PMID- 34862812
OWN - NLM
STAT- MEDLINE
DCOM- 20220316
LR  - 20220316
IS  - 1097-0347 (Electronic)
IS  - 1043-3074 (Linking)
VI  - 44
IP  - 2
DP  - 2022 Feb
TI  - The best choice of induction chemotherapy for patients with locally advanced 
      nasopharyngeal carcinoma: Bayesian network meta-analysis.
PG  - 518-529
LID - 10.1002/hed.26932 [doi]
AB  - The determination of the optimal induction chemotherapy (IC) regimen for patients 
      with locally advanced nasopharyngeal carcinoma (NPC) remains controversial. 
      Eligible trials included in this Bayesian network meta-analysis were judged by 
      synthetically evaluating survival and safety outcomes. The analysis revealed that 
      the combined IC regimen of gemcitabine plus cisplatin (GP) gained not only the 
      most favorable overall survival (OS) benefit but also longer distant 
      metastasis-free survival and manageable adverse events (AEs). Additionally, 
      combination IC regimen of mitomycin, epirubicin, cisplatin, fluorouracil, and 
      leucovorin had insufficient significant efficacy on complete response. Docetaxel 
      combined with cisplatin and fluorouracil induction regimen provided the first 
      exact probability of efficacy in term of local recurrence-free survival, ranking 
      second in OS, but accompanied by the highest rates of grade 3 or above AEs. GP 
      regimen appears to be currently the best choice of IC regimen for combined 
      benefit of patients with locally advanced NPC.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Liu, Ting
AU  - Liu T
AD  - Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Dai, Shuang
AU  - Dai S
AD  - Department of Medical Oncology, Lung Cancer Center, West China Hospital, Sichuan 
      University, Chengdu, China.
FAU - Zhang, Hao
AU  - Zhang H
AD  - Department of Pancreatic Surgery, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Zhong, Xi
AU  - Zhong X
AD  - Department of Critical Care Medicine, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Ding, Zhenyu
AU  - Ding Z
AD  - Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, 
      Chengdu, China.
FAU - Ma, Xuelei
AU  - Ma X
AUID- ORCID: 0000-0002-9148-5001
AD  - Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, 
      Chengdu, China.
AD  - Department of Biotherapy, State Key Laboratory of Biotherapy, West China 
      Hospital, Sichuan University, Chengdu, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20211204
PL  - United States
TA  - Head Neck
JT  - Head & neck
JID - 8902541
RN  - Q20Q21Q62J (Cisplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Bayes Theorem
MH  - Chemoradiotherapy
MH  - Cisplatin/therapeutic use
MH  - Fluorouracil/therapeutic use
MH  - Humans
MH  - *Induction Chemotherapy
MH  - Nasopharyngeal Carcinoma
MH  - *Nasopharyngeal Neoplasms/pathology
MH  - Network Meta-Analysis
OTO - NOTNLM
OT  - Bayesian
OT  - best choice
OT  - induction chemotherapy
OT  - locally advanced nasopharyngeal carcinoma
OT  - network meta-analysis
EDAT- 2021/12/05 06:00
MHDA- 2022/03/17 06:00
CRDT- 2021/12/04 08:34
PHST- 2021/10/18 00:00 [revised]
PHST- 2021/08/18 00:00 [received]
PHST- 2021/11/05 00:00 [accepted]
PHST- 2021/12/05 06:00 [pubmed]
PHST- 2022/03/17 06:00 [medline]
PHST- 2021/12/04 08:34 [entrez]
AID - 10.1002/hed.26932 [doi]
PST - ppublish
SO  - Head Neck. 2022 Feb;44(2):518-529. doi: 10.1002/hed.26932. Epub 2021 Dec 4.